Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation
Rita Brás, Célia Costa, Rita Limão, Leonor Esteves Caldeira, Marisa Paulino, Elisa Pedro
Topics & Concepts
OmalizumabMedicineDiscontinuationAngioedemaConfidence intervalRetrospective cohort studyAdverse effectInternal medicinePediatricsSurgeryGastroenterologyImmunologyImmunoglobulin EAntibodyUrticaria and Related ConditionsCoagulation, Bradykinin, Polyphosphates, and AngioedemaDrug-Induced Adverse Reactions